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Review Article
Role of Pelvic Lymph Node Dissection in Prostate Cancer Treatment
Jae Young Joung, In-Chang Cho, Kang Hyun Lee
Center for Prostate Cancer, National Cancer Center, Goyang, Korea
Pelvic lymph node dissection (PLND) is the most accurate and reliable staging proce-
dure for detecting lymph node invasion (LNI) in prostate cancer. Recently, [
11C]-choline 
positron emission tomography imaging and magnetic resonance imaging with lympho-
tropic superpara-magnetic nanoparticles have shown potential for detecting LNI but 
are still under investigation. The risk of LNI in low-risk groups could be underestimated 
by use of the current nomograms, which rely on data collected from patients who under-
went only limited PLND. Extended PLND (ePLND) shows higher lymph node yield, 
which leads to the removal of more positive nodes and fewer missed positive nodes. It 
may be possible to refrain from performing PLND on low-risk patients with a pros-
tate-specific antigen value ＜10 ng/ml and a biopsy Gleason score ≤6, but the risk of 
biopsy-related understaging should be kept in mind. Theoretically, meticulous ePLND 
may also impact prostate cancer survival by clearing low-volume diseases and occult 
micrometastasis even in pN0. The therapeutic role of PLND in prostate cancer patients 
is still an open question, especially in individuals with low-risk disease. Patients with 
intermediate- to high-risk disease are more likely to benefit from ePLND. 
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INTRODUCTION
Radical prostatectomy and pelvic lymph node dissection 
(PLND) and removal are important treatment options for 
men with clinically localized prostate cancer. The prog-
nostic significance of lymph node (LN) metastases is well 
established [1-4]. Pelvic LN metastasis is a strong prog-
nostic factor for disease progression and survival. Initially, 
PLND was performed in all patients during radical prosta-
tectomy. Historically, men who underwent surgery for clin-
ically localized prostate cancer have a 20% to 40% preva-
lence of pelvic LN involvement [5,6]. With the advent of 
prostate-specific antigen (PSA) testing and more wide-
spread prostate cancer screening programs since 1987, this 
rate has now decreased to 4% to 6% [7,8]. Currently, the ob-
jective of a staging lymphadenectomy is to identify micro-
metastatic spread to LNs for prognostic evaluation and to 
identify patients with LN metastasis who would benefit 
from immediate androgen deprivation therapy [9]. 
　At present, some urologists apply well-known nomo-
grams when they determine the need for PLND during rad-
ical prostatectomy [10-15]. Such nomograms help to identi-
fy those patients who need staging PLND but not when per-
forming radical prostatectomy. However, the diagnostic 
accuracy of the nomograms and their safety from an onco-
logic perspective are still unknown because of the lack of 
prospective randomized clinical trials. In contrast, others 
favor performing PLND in all patients for whom a radical 
prostatectomy is truly indicated [16]. To clarify this con-
fusion, the present study reviewed the available current 
literature on PLND to determine appropriate PLND candi-
dates, the optimal extent of PLND, and the clinical benefits 
of PLND.  
CLINICAL STGING FOR LYMPH NODE 
METASTASES
Despite advances in radiological technology, conventional 
computed tomography (CT) and magnetic resonance imag-
ing (MRI) are generally unreliable in detecting LN meta-Korean J Urol 2011;52:437-445
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FIG. 1. Pelvic lymph node dissection field including the (1) 
external iliac node, (2) obturator node, and (3) internal iliac 
node. Reproduced with permission [32].
stases due to their low sensitivity (0-30%). Positron emis-
sion tomography (PET) scanning can detect molecular 
changes as a result of metabolic changes found via the use 
of radiolabeled molecular probes that have different rates 
of cellular uptake. de Jong et al evaluated the tracer 
[
11C]-choline with PET imaging in 67 prostate cancer pa-
tients [17]. In 15 patients with biopsy-proven LN meta-
stasis, the tracer had a sensitivity rate of 80% and a specific-
ity rate of 96%. Another novel technique is high-resolution 
MRI used in tandem with the intravenous administration 
of lymphotropic superpara-magnetic nanoparticles, which 
potentially enables the identification of otherwise un-
detectable LN disease. Among 80 patients with localized 
and locally advanced prostate cancer, this technique had 
a 90.5% sensitivity rate and a specificity rate of 97.8% com-
pared with conventional MRI, which had a sensitivity rate 
of 35.4% and a specificity rate of 90.5% [18]. However, all 
false-negative nodes had a short-axis diameter of ＜5 mm 
when the sensitivity was only 41.1%. This promising tech-
nique cannot be used for routine application and requires 
further clinical validation before its widespread use [18]. 
Initially, several studies reviewing the 
111indium-labeled 
murine monoclonal antibody scan (ProstaScint
TM scan) 
showed that this technique has superior sensitivity and 
specificity compared with CT scans [19,20]. However, in 
patients with a lower stage (mean PSA, 16 ng/ml), 
ProstaScint
TM showed a very low positive predictive value 
(11%) and sensitivity (17%) for predicting LN invasion 
(LNI) [21].
　The sentinel LN concept has in recent years been applied 
to prostate cancer and was first introduced by Wawroschek 
et al [22]. This concept has an apparent sensitivity rate of 
96% for detecting lymphatic spread in node-positive pa-
tients [23]. However, this technique has its drawbacks. 
Only nodes in close contact with the collimator can be 
detected. If these nodes are not directly accessible, there 
is a large chance of them being missed.
　In summary, [
11C]-choline PET imaging or MRI with 
lymphotropic superpara-magnetic nanoparticles are prom-
ising but are still currently under investigation for clinical 
use. At present, there is no accurate or reliable imaging mo-
dality that can precisely detect LNI in prostate cancer 
patients. Thus, PLND represents the most accurate and re-
liable staging procedure for the detection of LNI in prostate 
cancer. 
EXTENT OF PLND
Anatomical studies have demonstrated that the prostate 
gland drains lymphatically into the periprostatic sub-
capsular network; this has been confirmed by nuclear med-
icine mapping studies [24-27]. For accurate diagnosis of no-
dal metastasis and possible cure of nodal disease, several 
templates for PLND have been described [28,29]. The most 
commonly used template for PLND in prostate cancer in-
cludes the removal of tissue along the external iliac vein 
and in the obturator fossa (Fig. 1) and is considered limited 
PLND (lPLND). The boundaries of the obturator fossa are 
the bladder (medially), the external iliac vein (laterally), 
the node of Cloquet (inferiorly), the bifurcation of the com-
mon iliac (superiorly), and the obturator nerve (posterio-
rly); these are collectively known as the external iliac nodes 
(diagram area 1). Standard PLND (sPLND) includes LNs 
in the obturator fossa and LNs deep and proximal to the 
obturator nerve (the obturator nodes; diagram area 2), 
whereas extended PLND (ePLND) also generally includes 
the tissue along the internal iliac vessels posteriorly (the 
internal iliac nodes; diagram area 3). Although some sur-
geons include the additional removal of subaortic and pre-
sacral nodes in their definition of ePLND [30,31],  ePLND 
is most commonly considered to be a node dissection that 
involves bilateral resection of the external iliac, obturator, 
and internal iliac nodal groups (1, 2 and 3, respectively in 
Fig. 1) [32].
　The total number of LNs removed during PLND is im-
portant for maintaining the accuracy of the staging 
procedure. More extensive dissections result in a greater 
LN yield. Weingärtner et al compared nodal counts in ca-
davers without prostate cancer subjected to PLND with ac-
tual counts resected during radical prostatectomy and 
PLND [33] and reported that, on average, 20 LNs must be 
removed for pathologic analysis to ensure an adequate and 
representative sample. An ePLND that involves the re-
moval of this volume of nodes provides enhanced accuracy 
as a staging procedure. An average LN yield of 21 nodes 
during ePLND was reported in one study [34], whereas an-
other study described an ePLND template including pre-
sacral and common iliac nodes in which the yield averaged 
28 LNs [31]. 
　To determine optimal templates of PLND in terms of ac-
curate diagnosis and possible cure of nodal disease, many 
studies of pelvic LNs have been performed. Bader et al 
showed data for positive LN location following ePLND 
along the external iliac vein, obturator nerve, and internal 
iliac vessels in 365 patients [32,34]. The most common site Korean J Urol 2011;52:437-445
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for metastasis (60%) was the obturator fossa. Overall, how-
ever, 58% and 36% of the patients had deposits in the in-
ternal iliac and external iliac nodal areas, respectively, 
whereas 19% had positive nodes distributed in the internal 
iliac vessels alone. Thus, if pelvic lymphadenectomy was 
confined to the obturator fossa, it would miss approx-
imately 60% of the metastases, because most of the histo-
pathologically proven metastatic LNs were found in the ex-
ternal and internal iliac node packets. Similar results were 
reported in a study that compared a historical series of pa-
tients who underwent lPLND with a contemporary series 
who underwent ePLND. That study reported that 42% of 
positive nodes were located outside the limited template 
[28,31]. Moreover, the authors determined that 25% of all 
positive LNs were exclusively located in the area around 
the internal iliac artery. 
　With respect to primary lymphatic landing sites, Mattei 
et al mapped the prostatic nodal landing zones by injecting 
Tc-99-labeled colloid into patients’ prostates [35]. They 
found that, even by using the extended template, approx-
imately one-third of the primary landing sites would still 
be missed and advocated including the tissue along the 
common iliac vessels up to the crossing of the ureter. For 
accurate staging including all primary lymphatic draining 
sites, the field of LN dissection should theoretically include 
tissue up to the origin of the inferior mesenteric artery.
　In contrast, Clark et al performed a prospective random-
ized evaluation of 123 patients undergoing radical prosta-
tectomy to assess the diagnostic value of an ePLND involv-
ing the presacral area compared with sPLND for detecting 
nodal metastasis [30]. On the basis of eight patients in 
whom LN metastasis was confirmed histopathologically, 
they concluded that ePLND did not improve the accuracy 
of LN staging compared with sPLND. This is the only study 
to date that was designed to be prospective and random-
ized; however, the majority of the patients presented with 
low-risk prostate cancer with a low rate of LNI. Further-
more, ePLND was performed on only one side, and no data 
were given regarding the number of LNs removed from 
each group.
　To measure the exact LN yield following PLND, an addi-
tional factor to consider is the pathological examination 
method. In bladder cancer studies, greater nodal yields 
have been noted when lymphadenectomy specimens are 
sent as separate packets (such as external iliac and ob-
turator) rather than en bloc [36,37]. Separate examination 
of specimens is an important procedure for optimizing LN 
detection and provides an accurate determination of nodal 
tumor burden [36,38].
　In summary, more extensive dissection results in in-
creased LN yield. As more nodes are removed, more pos-
itive nodes are found and fewer positive nodes are missed. 
For more accurate staging and a possible cure for minimal 
nodal disease, more extensive PLND could be used. 
However, based on the knowledge of primary lymphatic 
landing sites, many lymph nodes would still be missed even 
with ePLND.
FOR WHICH PATIENTS IS PLND NECESSARY?
After the introduction of PSA testing, the rate of LNI dra-
matically decreased to about 4% to 6% [7,8]. In Korea, the 
reported incidence of LNI by sPLND is between 4% and 6%. 
Kim et al reviewed their experience with 1,324 radical pros-
tatectomy cases and reported that that 6% of patients had 
LNI [39]. Ham et al investigated 273 patients who under-
went robotic prostatectomy. Among them, 11 patients (4%) 
showed LNI [40]. In our institution, of 351 patients who un-
derwent limited or standard PLND, LNI was determined 
in 20 (5.7%) patients (unpublished data). With lower rates 
of pelvic LN metastasis [7,8] and the potential complica-
tions that can develop after PLND [30,41], knowing which 
prostate cancer patients need to undergo PLND regret-
tably remains undetermined. Several nomograms have 
been designed to predict LNI (Table 1) and to identify pa-
tients who may derive the most benefit from PLND [10-15, 
42-51]. Most nomograms, including the well-known Partin 
tables [12,52] and Memorial Sloan-Kettering nomograms 
[42], predict pathologic stage by using preoperative clinical 
stage, biopsy Gleason scores, and preoperative PSA levels 
[12-14,42,53,54]. However, although these nomograms are 
well established and are certainly useful for the clinical de-
cision making process, the predictive ability of most nomo-
grams, except for two, is limited by the data used to create 
them. Most datawere obtained from series of lPLND with 
a mean of 6 to 9 LNs removed (Table 1) [10-15,42-52]. 
Therefore, the true prevalence of LNI may be significantly 
underestimated owing to the limited nodal sampling. 
Heidenreich et al compared 103 patients who underwent 
ePLND with 100 patients who received only sPLND in 
which no significant differences in age, preoperative PSA 
levels, or mean biopsy Gleason scores existed [31]. They re-
ported that ePLND was associated with a high rate of LN 
metastasis outside of the fields of sPLND in cases of clin-
ically localized prostate cancer [31]. Similarly, other stud-
ies also found that nomograms based on sPLND, where in-
ternal iliac nodes were not sampled, could not be considered 
a reliable method because sPLND could miss 25% to 50% 
of the positive nodes compared with extended dissection 
[31,32,53,55,56].
　A Korean multi-institutional study developed a nomo-
gram to predict LNI [57]. But, the nomogram was also 
based on sPLND and so could only predict the pathological 
stage of the clinically localized prostate cancer. To over-
come this limitation, Briganti et al created and validated 
a nomogram that estimates the optimal number of nodes 
that should be removed based on clinical parameters and 
the number of nodes removed during ePLND [53,55]. From 
internal validation with 602 patients, their nomogram 
demonstrated an accuracy of 76% based on ePLND [53]. 
Within the same groups of risk from the D’Amico classi-
fication system [58], significantly higher LNI predictions 
using the Brigantin nomogram are likely, in part due to the 
ePLND data used to generate them. However, its reli-
ability may be decreased by the fact that the majority of pa-Korean J Urol 2011;52:437-445
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TABLE 1. Nomograms for predicting the lymph node involvement in prostate cancer 
Study
No. of 
patients
Predictors
Extent of 
PLND
Prevalence of 
LNI, %
Predictive
 accuracy, %
Cagiannos et al [42]
Kattan et al [4,10,11,33,51]
Makarov et al [12]
Briganti et al [13,41,53,55]
Briganti et al [13,41,53,55]
Bluestein et al [14]
Bishoff et al [43]
Narayan et al [44,45]
Conrad et al [54,15]
Roach et al [45]
Crawford et al [9,46,47]
Batuello et al [46,47]
Han et al [8,47,48]
Poulakis et al [49]
Karam et al [50]
Wang et al [51]
7,014
   697
5,730
   602
   278
1,632
   481
   932
   344
   212
4,133
6,135
5,744
   201
   425
   411
PSA, clinical stage, biopsy Gleason score
PSA, clinical stage, biopsy Gleason score
PSA, clinical stage, biopsy Gleason score
PSA, clinical stage, biopsy Gleason score
PSA, clinical stage, biopsy Gleason score, 
  percentage of positive cores
PSA, clinical stage, biopsy Gleason score
PSA, clinical stage, biopsy Gleason score
PSA, biopsy Gleason score
No. of positive biopsies, no. of biopsies
  containing any Gleason grade  4 or 5 cancer
PSA, biopsy Gleason score
PSA, clinical stage, biopsy Gleason score
PSA, clinical stage, biopsy Gleason score
PSA, clinical stage, biopsy Gleason score, age
PSA, clinical biopsy Gleason score, 
  and pelvic coil MRI findings
PSA, clinical stage, biopsy Gleason score, 
  preoperative plasma endoglin
PSA, clinical biopsy Gleason score, 
  and pelvic coil MRI findings
Limited
Limited
Limited
Extended
Extended
Limited
Limited
Limited
Limited
Limited
Limited
Limited
Limited
Limited
Limited
Limited
     3.7
  8
  1
11
  10.4
NA
     7.7
11
     8.1
17
NA
     4.6
  5
10
     3.3
  5
76
   76.8
88
76
83
NA
NA
NA
NA
NA
NA
81
88
91
   97.8
   89.2
PLND: pelvic lymph node dissection, LNI: lymph node invasion, PSA: prostate-specific antigen, MRI: magnetic resonance imaging, 
NA: not available
TABLE 2. Guidelines for determining the need for and extent of pelvic lymph node dissection for treating prostate cancer
Guidelines Indication for PLND
Extent of 
PLND
European Association of
  Urology
American Urological 
  Association
National Comprehensive
  Cancer Network
Men with intermediate (cT2a, PSA 10-20 ng/ml, biopsy Gleason score 7) or high-risk
  (＞cT2b, PSA ＞20 ng/ml, Gleason score ≥8) prostate cancer
PLND generally reserved for patients with higher risk of nodal involvement
PLND can be excluded in patients with ＜7% predicted probability of lymph node
  metastases by nomograms although some patients with nodal metastases will
  be missed. An extended PLND is preferred when PLND is performed
Extended
Not indicated
Extended
PLND: pelvic lymph node dissection, PSA: prostate-specific antigen
tients qualified as low-risk patients, and only 9% (71 pa-
tients) were LN-positive and ePLND was performed in only 
23% of patients.
　  The necessity for PLND has been questioned, particularly 
in low-risk groups, on the basis of studies of lPLND. On the 
contrary, studies with ePLND have shown that LN meta-
stases can occur even in patients with a PSA level ＜10 
ng/ml. Schumacher et al showed that following ePLND and 
radical prostatectomy in patients with PSA ＜10 ng/ml, 
there was a 25% incidence of LN metastases in those with 
a specimen Gleason score ≥7, whereas only 3% of patients 
with a Gleason score ≤6 were node-positive [59]. Heiden-
reich et al reported a 2.4% incidence of LN metastasis in 
patients with a PSA level ＜10.5 ng/ml and biopsy Gleason 
scores ≤6, whereas Bhatta-Dhar et al found that the LN 
metastasis risk was ＜1% after lPLND in a series of pa-
tients with organ-confined disease, PSA ＜10 ng/ml, and 
a biopsy Gleason score ≤6 [31,60]. However, the inherent 
risk of understaging, which is approximately 30% [61], has 
to be taken into account. In the study of Bhatta-Dhar et al, 
40% of patients had their Gleason scores upgraded to ＞6 
[60]. 
　Expert panels from the American Urological Associa-
tion, National Comprehensive Cancer Network, and 
European Association of Urology have created guidelines 
for PLND based on such nomograms and other available 
data (Table 2). In summary, several well-known nomo-
grams can be used to accurately predict who is at risk for 
LN-positive prostate cancer and to potentially predict who 
might derive therapeutic benefit from PLND. However, by 
depending on these nomograms, we may fail to properly 
stage patients with apparently low-risk disease because Korean J Urol 2011;52:437-445
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these nomograms rely on data collected from patients who 
only underwent lPLND. Overall, the existing data suggest 
that it may be possible to refrain from performing PLND 
on low-risk patients with a PSA ＜10 ng/ml and a biopsy 
Gleason score ≤6, but the inherent risk of biopsy-based un-
derstaging should be kept in mind.
THERAPEUTIC ROLE OF PLND
Aside from providing clinicians with the most accurate LN 
staging, the therapeutic role of PLND in prostate cancer 
is another main issue. Some evidence suggests that ePLND 
might also have a positive impact on survival. Early studies 
suggested that radical prostatectomy and removal of in-
volved regional LNs was beneficial for survival [62,63]. A 
subsequent study confirmed a 68% 10-year metastasis- 
free survival rate in patients with LN micrometastasis who 
were managed without adjuvant therapy [64], indicating 
that radical prostatectomy with PLND could be curative 
even for LN-positive disease. Theoretically, these results 
are supported by the fact that meticulous nodal resection 
removed micrometastases not detected by routine patho-
logic examination, which may in part be explained im-
munohistochemically [65]. The latter study was a careful 
review of 3, 914 negative nodes from 274 pT3 patients by 
immunohistochemical staining. The authors reported that 
13.3% of 180 patients who were originally defined as being 
N0 actually harbored occult LN metastasis. These patients 
had significantly poorer survival rates than did patients 
who were truly LN-negative and had outcomes comparable 
to men who had been LN-positive on initial staging. Ferrari 
et al used a real-time polymerase chain reaction (PCR) as-
say that revealed and quantified occult micrometastases 
in pathologically negative LNs before primary therapy for 
prostate cancer [66]. Terakawa et al also found that re-
al-time PCR increased the detection rate of LNI by more 
than three-fold compared with routine immunohistoche-
mistry [67]. These authors also demonstrated a statistical 
correlation between occult (real-time PCR-detected) LNI 
and patient outcomes.
　With respect to the correlation between the burden of 
positive node removal and prognosis following radical pros-
tatectomy and PLND, Bader et al determined the pro-
gression and survival rates of 92 patients with positive no-
des following radical prostatectomy and ePLND without 
adjuvant therapy [32]. Following a median follow-up of 45 
months, 15 of 39 patients (38.5%) with a single positive 
node did not show signs of progression, whereas only 10% 
and 14% of patients with two or more positive LNs, re-
spectively, remained disease free. Other studies reported 
the possibility of long-term survival despite the presence 
of limited LN metastasis with PLND and poorer prognosis 
with greater LN invasion [8,28,68-72]. Daneshmand et al 
reported that patients who had one or two positive LNs had 
a clinical recurrence-free survival rate of 70% and 73%, re-
spectively, after 10 years compared with men with five or 
more involved nodes, who had a recurrence-free survival 
rate of only 49% [68]. A positive node density ＜20% was 
associated with improved disease progression rates and 
survival. Allaf et al reported that among men with LN-pos-
itive disease involving ＜15% of extracted nodes, the 5-year 
PSA progression-free rate for ePLND was 43% compared 
with 10% for the more limited PLND [69]. Boorjian et al ret-
rospectively reviewed a large series of patients with pos-
itive LNs after radical prostatectomy and PLND with a lim-
ited number of nodes (median 11) removed and found that 
56% of the patients had a 10-year biochemical pro-
gression-free survival period. A solitary LN metastasis in-
creased the risk of cancer-specific death almost four-fold; 
in patients with two or more positive LNs, this was in-
creased two-fold compared with patients with only one pos-
itive node [71]. Palapattu et al found that 52% of men with 
a positive node density of ＜15%, a Gleason score ≤7, and 
no seminal vesicle invasion remained free of biochemical 
failure after 5 years [72].
　Furthermore, in patients with pN0 prostate cancer, 
Masterson et al found that an increased number of nodes 
removed significantly correlated with the absence of bio-
chemical recurrence [73]. Similarly, Joslyn and Konety, us-
ing the SEER database, revealed that when age, race, 
stage, grade, and radiotherapy were controlled for, the risk 
of cancer-specific death was significantly lower (23%) for 
patients who had more than four LNs removed [70]. Furth-
ermore, more extensive lymphadenectomy (＞10 nodes re-
moved) was associated with a 15% lower risk of prostate 
cancer death even after the analysis was restricted to pa-
tients with negative lymph nodes. Early data from a recent 
case-control series by Heidenreich et al [28] also demon-
strated a therapeutic benefit of ePLND. By comparing a co-
hort of 100 consecutive patients with pN0 disease who un-
derwent lPLND with a group of 100 consecutive patients 
who underwent ePLND with minimum of 5 years of fol-
low-up, the initial data obtained indicated a PSA relapse 
rate of 23% in the lPLND group compared with 8% in the 
ePLND group.
　In contrast, other studies could not define the ther-
apeutic role of PLND in prostate cancer. Bhatta-Dhar et al 
did not show any benefit of PLND. They retrospectively re-
viewed 336 patients with favorable tumor characteristics 
such as PSA levels of 10 ng/ml or less, biopsy Gleason scores 
≤6, and clinical stage of T1 or T2 [60]. They determined 
that the 6-year biochemical relapse-free rate was not sig-
nificantly different between patients who underwent 
PLND and those who did not. However, this study had some 
limitations including an absence of randomization, the 
lack of removal of internal iliac nodes (which is crucial in 
PLND), and the fact that the cohort was confined to only 
patients with a low risk for LN metastasis. DiMarco et al 
did not find improvement in prostate cancer outcomes with 
increasing LN yield between lPLND and ePLND in an ad-
juvant therapy-free cohort of 7,036 pN0 patients [74]. More 
recent data from Murphy et al corroborated that LN yield 
was not a predictor of biochemical recurrence in pN0 pa-
tients, even when the patients were stratified into high- Korean J Urol 2011;52:437-445
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and low-risk groups [75]. The Weight et al study of low-risk 
patients suggested that there was no difference in the 
10-year actuarial biochemical recurrence-free outcomes 
between a low-risk cohort at the Cleveland Clinic and those 
who underwent lPLND and no PLND based on surgeon 
preference [76]. Berglund et al searched the Cancer of the 
Prostate Strategic Urologic Research Endeavor (CapSURE) 
observational database to find evidence that lPLND might 
impact biochemical recurrence after 5 years compared 
with no PLND [77]. Multivariate analysis demonstrated 
that performance of lPLND was not a predictor of bio-
chemical recurrence in low-risk, intermediate-risk, or 
high-risk groups.
　Although many studies have examined the therapeutic 
role of PLND in treating prostate cancer, the question of 
whether low-risk patients benefit from PLND is still open. 
In contrast, men with intermediate- to high-risk prostate 
cancer appear more likely to benefit from ePLND, prognos-
tically and perhaps even therapeutically. Greater nodal re-
moval may also impact patient survival by the therapeutic 
effect of superior disease clearance, especially in patients 
with low-volume LN invasion or even in pN0 patients. In 
addition, removing as many nodes as possible should be the 
main objective of PLND for improving outcomes as well as 
detecting metastatic LNs.
COMPLICATIONS OF PLND
  Complications of PLND include lymphocele, deep vein 
thrombosis, hematoma, pulmonary edema, ureteral in-
jury, and obturator nerve injury. Complication rates for 
PLND range from 2% to 51% in different series [41]. The 
most commonly described complication is lymphocele 
[34,55]. Briganti et al compared the complication rates of 
extended (n=767) and limited (n=196) dissection and found 
that the lymphocele formation rates were 10.3% and 4.6%, 
respectively [41]. Lymphocele formation and prolonged 
length of stay were the only complications that were sig-
nificantly higher in patients who underwent ePLND. Clark 
et al compared complication rates by randomly assigning 
123 patients undergoing open radical prostatectomy to 
have ePLND on one side of the pelvis and lPLND on the oth-
er [30]. They showed that a complication rate of 10% was 
attributable to PLND, with complications occurring three 
times more often with ePLND than with lPLND. In con-
trast, Heidenreich et al demonstrated that the overall in-
cidence of intra- and perioperative complications was sim-
ilar for limited and extended PLND [31,78]. To avoid 
PLND-associated morbidity, the following suggestions 
have been made: (1) instead of using clips, which are often 
torn away during subsequent surgery, all lymphatics com-
ing from the lower limb should be ligated; (2) all lymphatics 
lateral to the external artery should be saved; and (3) two 
drains should be placed on each side of the pelvis that are 
not removed until the total volume of secretion is ＜50 ml 
per day. In addition, injection of low molecular weight hep-
arin into the arm and not the lower limb may help to reduce 
the incidence of lymphocele formation [79].
CONCLUSIONS
Currently, PLND is the most accurate and reliable staging 
procedure for detecting LNI in prostate cancer. We believe 
that an extended template might be appropriate for PLND 
in cases of prostate cancer due to higher LN yield, increased 
removal of positive nodes, and fewer missed positive nodes. 
Existing data suggest that it may be possible to refrain from 
performing PLND in low-risk patients with PSA levels 
＜10 ng/ml and biopsy Gleason scores ≤6, but the risk of 
biopsy-related understaging should be noted. The ther-
apeutic role of PLND in prostate cancer is still an open ques-
tion, especially in low-risk cases. Patients with inter-
mediate- to high-risk disease are likely to benefit from 
ePLND, even therapeutically.
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